These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto-prostatectomy]. Llopis J; Romero JA; Gutiérrez R; Alvarez R; Talbot R; Vendrell JR; Barranco MA; Carretero P J Urol (Paris); 1995; 101(2):104-6. PubMed ID: 8522852 [TBL] [Abstract][Full Text] [Related]
3. [Methylene blue: an effective therapeutic alternative for priapism induced by intracavernous injection of vasoactive agents]. Martínez Portillo FJ; Fernández Arancibia MI; Bach S; Alken P; Jünemann KP Arch Esp Urol; 2002 Apr; 55(3):303-8. PubMed ID: 12068762 [TBL] [Abstract][Full Text] [Related]
4. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1. Buvat J; Lemaire A; Herbaut-Buvat M Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388 [TBL] [Abstract][Full Text] [Related]
5. [Management of priapism induced by PGE1]. Guzman Martínez-Valls PL; Tomas Ros M; Ferrero Doria R; Morga Egea JP; Navas Pastor J; Rico Galiano JL; Sempere Gutierrez A; Fontana Compiano LO Arch Esp Urol; 1998 Jun; 51(5):457-60. PubMed ID: 9675941 [TBL] [Abstract][Full Text] [Related]
6. The incidence and management of priapism in Western Australia: a 16 year audit. Earle CM; Stuckey BG; Ching HL; Wisniewski ZS Int J Impot Res; 2003 Aug; 15(4):272-6. PubMed ID: 12934055 [TBL] [Abstract][Full Text] [Related]
7. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. McMahon CG Int J Impot Res; 2003 Oct; 15(5):383-4. PubMed ID: 14562142 [No Abstract] [Full Text] [Related]
8. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184 [TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Schramek P; Dorninger R; Waldhauser M; Konecny P; Porpaczy P Br J Urol; 1990 Jan; 65(1):68-71. PubMed ID: 2310934 [TBL] [Abstract][Full Text] [Related]
10. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Kulmala RV; Tamella TL Int J Impot Res; 1995 Jun; 7(2):131-6. PubMed ID: 7496442 [TBL] [Abstract][Full Text] [Related]
14. Priapism after transurethral alprostadil. Bettocchi C; Ashford L; Pryor JP; Ralph DJ Br J Urol; 1998 Jun; 81(6):926. PubMed ID: 9666789 [No Abstract] [Full Text] [Related]
15. Intracorporeal phenylephrine in the treatment of priapism. Muruve N; Hosking DH J Urol; 1996 Jan; 155(1):141-3. PubMed ID: 7490814 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction. Cawello W; Schweer H; Dietrich B; Seyberth HW; Albrecht D; Fox A; Hohmuth H J Urol; 1997 Oct; 158(4):1403-7. PubMed ID: 9302131 [TBL] [Abstract][Full Text] [Related]
17. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. Porst H J Urol; 1996 Mar; 155(3):802-15. PubMed ID: 8583582 [TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187 [TBL] [Abstract][Full Text] [Related]
19. [Priapism of low flow]. Ruiz Cerda JL; Moreno Pardo B; Server Pastor G; Osca García JM; Vera Donoso C; Jiménez Cruz JF Actas Urol Esp; 1991; 15(6):510-4. PubMed ID: 1792989 [TBL] [Abstract][Full Text] [Related]
20. [Iatrogenic priapism caused by intracavernous injection of vasoactive drugs in the treatment of impotence]. Bondil P Presse Med; 1986 Apr; 15(14):665. PubMed ID: 2939440 [No Abstract] [Full Text] [Related] [Next] [New Search]